Women Who Had Depo-Provera Injections Before December 2025 Label Change Can Still Sue Responsible Pharmaceutical Drug Companies

(Posted by Tom Lamb at Drug Injury Watch)

In December 2025, a Depo-Provera “meningioma warning” label change was required by the FDA to be made by the responsible pharmaceutical drug companies. This Depo-Provera label change is a factor for the Depo-Provera meningioma side-effect lawsuits filed in the past year or two. Furthermore, the Depo-Provera label change may lead people to ask whether new Depo-Provera lawsuits can be filed in 2026, now that there is a meningioma warning in the Depo-Provera drug label.

The answer is “yes”: a woman diagnosed with meningioma after getting Depo-Provera injections can file a new Depo-Provera lawsuit in 2026 — under certain circumstances. One critical factor is that the woman received Depo-Provera injections before December 2025, when this Depo-Provera meningioma warning was added to the drug label.

From the current FDA-approved Depo-Provera Prescribing Information “Revised 12/2025” version (PDF document), in its Warnings and Precautions section:

5.4 Meningioma
Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long term use. Monitor patients on Depo-Provera CI for signs and symptoms of meningioma. Discontinue Depo-Provera CI if a meningioma is diagnosed.

Two important points about what this Depo-Provera meningioma warning added in 2025 means for new Depo-Provera lawsuits in 2026 and future years:

• First, to be clear, before the December 2025 label change, there was no Depo-Provera meningioma warning in the (previous) Depo-Provera Prescribing Information documents.
• Second, there is delay, or so-called “latency period”, from the time when a woman has Depo-Provera injections until that woman is diagnosed with meningioma.

Accordingly, women who used Depo-Provera before December 2025 can file new Depo-Provera lawsuits in 2026 alleging failure to warn about the meningioma side effect, regardless of whether their meningioma diagnosis was made before or after the December 2025 Depo-Provera “meningioma warning” label change.

That may be a bit complicated, but as stated above, the answer is “yes”, a woman diagnosed with meningioma after getting Depo-Provera injections can file a new Depo-Provera lawsuit in 2026 under certain circumstances.

__________________________________________________________________

Depo-Provera Contraceptive Injection

Free Case Evaluation

Strictly Confidential, No Obligation.

__________________________________________________________________

Here are some other factors for the Depo-Provera meningioma lawsuits filed against the responsible pharmaceutical drug companies:

(A) The woman must have received at least 1 injection of any of the following:

• Brand name Depo‐Provera 150mg IM Injections (Upjohn, Pharmacia, Pfizer)
• Brand name Depo‐SubQ 104 Provera (Upjohn, Pharmacia, Pfizer)
• An “authorized generic” version of Depo‐Provera manufactured by Pharmacia & Upjohn Company LLC, Greenstone LLC, or Prasco Laboratories

(B) The woman must have received a diagnosis made by a doctor of one or more of these medical conditions:

Meningioma
Intracranial meningioma
Intercranial meningioma
Cranial meningioma
Brain meningioma
Meninges tumor
Arachnoid tumor (but not arachnoid cyst)
Convexity meningioma
Falcine meningioma
Parasagittal meningioma
Intraventricular meningioma
Skull base meningioma
Sphenoid wing meningioma
Olfactory groove meningioma
Posterior fossa/petrous meningioma
Suprasellar meningioma
Recurrent meningioma
Foramen magnum meningioma
Meningothelial meningioma
Fibrous meningioma
Psammomatous meningioma
Angiomatous meningioma
Secretory meningioma

We have written previously on this Drug Injury Watch site about the medical and legal aspects of Depo-Provera meningioma cases:

Meningioma Warning For Depo-Provera Recommended in Europe by Drug Regulator — Why Has This September 2024 European Medicines Agency (EMA) Action Not Been Followed by FDA in US?

Depo-Provera Drug Label Warnings in US Do Not Include Increased Risk of Intracranial Meningioma — While European Union (EU) and United Kingdom (UK) Drug Labels Have Warned About Meningioma for Many Years

Side Effects of Birth Control: Brain Tumors Related to Depo-Provera Contraceptive Injections — Intracranial Meningioma Risks Are Increased When Depo-Provera Was Used for More Than One Year

We are investigating Depo-Provera meningioma cases for women who are seeking legal compensation from the responsible pharmaceutical companies. We point out that these Depo-Provera meningioma lawsuits would not be filed against the doctors who prescribed the Depo-Provera injections because the failure to warn about the meningioma side effect was not disclosed until December 2025.

You can submit an Online Case Evaluation Form for a possible Depo-Provera meningioma lawsuit, or call 910-256-2971 to speak with attorney Tom Lamb about your Depo-Provera meningioma case.

DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects

Drug Injury Case Evaluation – Free. Confidential. No Obligation.